Navigation Links
United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery

NEW YORK, Nov. 19, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology Research Objectives

•Understand trends, dynamics, and parameters specific to the delivery of drugs to cancer patients in key treatment settings such as home, office, or infusion center.
•Identify physician prescribing trends relative to drug delivery considerations.
•Understanding the role of reimbursement in physician's choice of drug delivery.
•Identify physicians' perception of different drug delivery approaches, as well as key drivers for adoption/non-adoption, compliance, and choice of delivery devices.
•Identify drug delivery trends within the oncology area.
•Determine product attributes relative to delivery that are considered to be important by physicians and patients.
•Identify prospective patient preferences and willingness to try new technologies as well as determine key drivers of adoption/non-adoption.

Industry Background

Drug delivery is an important area of drug development in the pharmaceutical and biotechnology industry. In oncology, developers are interested in understanding the opportunities and parameters for delivery of drugs in outpatient settings, particularly in the home. This is important for biotechnology products used in this area as companies seek to design new products and evaluate new opportunities for targeted therapies and other cancer treatments.

Scope: Drug Delivery Categories

The eleven drug delivery categories evaluated in this research are:
•Intravenous injection
•Subcutaneous (SC) injection
•Intramuscular (IM) injection
•Intravenous infusion
•Implantable infusion pump
•External infusion pump
•Transdermal patch
•Topical gel or cream

Executive Summary

•Across all cancer types, oral is currently the dominant ( percent) mode of drug delivery. Meanwhile, the availability and prescription of effective implantable infusion pump as an oncology drug delivery mode has the potential for higher patient acceptance compared to external infusion pump. However, a significant proportion ( percent) of patients who are unwilling to use external infusion pumps will still comply if the method is prescribed by a doctor.
•While cancer patients are least familiar with topical gel or cream for oncology treatment, percent of respondents reported that they would be willing to use this method for future oncology treatments, implying a potential for high growth rate.
•Although external infusion pump remains in the top three most utilized oncology drug delivery methods, utilization rates within cancer types has decreased.

•For Lung Cancer, oral is currently the dominant ( percent) delivery method. Since topical gel or cream has a high utilization rate ( percent), high satisfaction rate ( percent), and a strong rate ( percent) of willingness to use, it appears that topical gel or cream could be positioned to grow as an oncology drug delivery method of choice for lung cancer patients.
•Although it is not a top-three treatment option, rectal drug delivery has the overall highest utilization rate when comparing mean scores ( ) among all cancer types, implying a potential for market share growth.
•Lung cancer patients are least familiar with external infusion pump ( percent) for oncology treatment, and only half of respondents report that they are willing to use external infusion pumps for future oncology treatments.

•For Colorectal Cancer, external infusion pump delivery is currently dominant. Although the most-used oncology drug delivery methods among colorectal cancer patients are invasive, these patients prefer non-invasive treatment options the most: transdermal patch ( percent), topical gel/cream (86 percent), and oral ( percent).
•The potential to increase the usage of transdermal patches is high, considering the high proportion of willing users and that there is high satisfaction with this drug delivery method.
•External infusion pump is used more often by colorectal cancer patients than any of the other surveyed cancers.

Table of Contents

Slide Numbers
Research Objectives and Methods
Executive Summary and Implications

Profile of Respondents

Awareness and Utilization of Oncology Drug Delivery Methods

Perceptions, Attitudes and Willingness to Use Drug Delivery Methods

Preference for and Satisfaction with Drug Delivery Methods

Preferred Setting for Treatment

Profile of Patients' Compliance

Criteria of Drug Delivery Selection

The Frost & Sullivan Story

To order this report:
Drug_Delivery_Technology Industry: United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery 

Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
3. Eleven Integrated Health Systems Form Largest Private-Sector Diabetes Registry in United States
4. United Spinal To "Roll on Capitol Hill:" Voices Aim to Impact Federal Health Care Policy
5. United States ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
6. Zimmer Introduces First Porous Metal Interbody Implant for Lumbar Spine in the United States
7. United Kingdom ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
8. United States Surgical Equipment Market Outlook to 2018- Electrosurgical Devices, Hand Instruments and Surgical Sutures
9. United States Market for Psoriatic Arthritis Pharmacotherapy
10. 2012 United States Medical Devices Outlook
11. Celladon Corporation Receives Patent from United States Patent and Trademark Office
Post Your Comments:
(Date:11/24/2015)... -- Sectra (STO: SECT B) announces that ... multi-year agreement to deploy Breast Imaging PACS in ... the Breast Center a future-proof platform capable of expanding with ... announces that Breast Center of Acadiana has entered ... PACS in its two freestanding imaging centers. This investment will ...
(Date:11/24/2015)... , November 24, 2015 ... --> adds Latest Guidebook for Chinese ... 217 pages published in November 2015 to the ... business intelligence library at . ... the fastest growing global economies with a fifth ...
(Date:11/24/2015)... F1000Workspace - a research collaboration, ... was launched just six months ago. --> F1000Workspace ... for scientists - since it was launched just six months ... on to F1000Workspace - a research collaboration, reference ... launched just six months ago. --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a ... sleep tracking systems. The new app features a more intuitive SleepScore™ that rates sleep ... well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
(Date:11/25/2015)... Md (PRWEB) , ... November 25, 2015 , ... ... Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for ... of this disease. The Periwinkle Pioneers, nominated by the public, will receive special ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... on providing comprehensive solutions involving adult stem cell therapies to patients with chronic ... the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required to ...
Breaking Medicine News(10 mins):